Lauri Strauss Leukemia Foundation Endowed Fellows
At Memorial Sloan Kettering Cancer Center, New York, NY

The Lauri Strauss Leukemia Research fully endowed Fellowship at Memorial Sloan Kettering Cancer Center, designed for a clinical investigator in leukemia and allied cancers, offers academically oriented physician training in medicine with clinical investigation and basic science research.
This endowment provides funding for training in comprehensive care of the patient. Established in 1997 twelve Fellows have been working on fifteen individual Projects.
Thomas J. Gardner, PhD
2017 -
Memorial Sloan Kettering Cancer Center, New York, NY Modeling Novel Translocations in Hematopoetic
Malignancies Using CIRPSR/Cas9.

Melissa Mathias, MD
2017 -
Memorial Sloan Kettering Cancer Center, New York, NY Developing Targeted Immunotherapy for Leukemia Oncoproteins

Leonid Dubrovsky, MD
2013 - 2015 -
The Treatment of CML with Antibodies

Jae Park, MD
2010 - 2011 -
Optimizing Adoptive Therapy with CD19  Targeted T Cells in Patients with
B Cell Leukemias and Lymphomas.

Prabodhika Mallikaratchy, PhD
2009 - 2010 -
Developing a new drug for chronic leukemia.

Tod Rosenblat, MD
2007- 2009 –
Studying novel clinical trials of AML with antibody based radiotherapy.

Lei Zhu, PhD
2006 - 2007 –
Development of y-Secretase inhibitors as novel anti-leukemia therapeutics.

Debjit Chattopadhyay, PhD
2005 - 2006
– Developing new methods to deliver drugs selectively to leukemia cells using novel nanomaterials.

Deborah Mulford, MD
2003 - 2005 -
Review of treatments for AML.

John M. Burke, MD
2001 - 2003
- In clinical trials radio labeled antibodies will be used to treat patients with certain types of acute and chronic leukemias.

Timothy Aliff, MD
2000 - 2001
– The study of new combination chemotherapy approaches for acute lymphocytic leukemia.

Steven Novick, MD, PhD
2000 - 2001
– Investigating novel treatment strategies for chronic leukemia.

Renier Brentjens, MD
1999 - 2000
– . The plan is to genetically engineer human T cells so that they will recognize and destroy human leukemia cells. The project is on the cutting-edge of genetics and immunotherapy research.

Robert Sokolic, MD
1999 - 2000 –
The primary goal of this research is to investigate the proteins that are involved in the regulation of cell death in leukemia cells.

Steven Kossman, MD
1998 - 1999
– Development of a comprehensive treatment program for chronic leukemias focused on curative strategies that employ the combination of chemotherapy and immunologic techniques.

Elsje Barensdwaard, MD
1997 - 1998
– Preliminary experiments with the anti CD-19 antibody SJ25C1, when radiolabeled with Yttrium-90, show in vitro killing of B-cell lymphomas, compared with radiolabeled control antibody treatment.

  The Lauri Strauss Leukemia Research Fellowship Endowment provides an excellent opportunity to have a significant impact upon the training of future leaders in leukemia and allied cancer research and treatment, thus providing essential support for Memorial Sloan Kettering Cancer Center in its effort to achieve the progressive control and cure of the disease.
Email Us For More Information